Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study

• Main Authors: Rand A. Alattar (Author), Shiema Abdalla (Author), Tasneem Abdallah (Author), Rashid Kazman (Author), Aseelah Qadmour (Author), Tawheeda Ibrahim (Author), Bassem Alhariri (Author), Shahd H. Shaar (Author), Abeer Bajwa (Author), Abeir Alimam (Author), Rabia Qazi (Author), Fatma Ben Abid (Author), Joanne Daghfal (Author), Ali Eldeeb (Author), Kinda Shukri (Author), Ahmed Elsayed (Author), Fatima Rustom (Author), Musaed Alsamawi (Author), Alaaeldin Abdelmajid (Author), Miguel A.P. Basulto (Author), Armando A.R. Cobian (Author), Mohamed Abukhattab (Author), Abdullatif Alkhal (Author), Muna A. Almaslamani (Author), Ali S. Omrani (Author)
• Format: Book
• Published: Elsevier, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary out...